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Abstract
Background: The study aims to assess the pattern of thyroid response to combination Interferon-
α2β (IFN-α) and Ribavirin (RBV) anti-viral therapy in an Australian hepatitis C cohort. These
include the prevalence of thyroid dysfunction (TD) including hyperthyroidism and hypothyroidism
and their possible predictors, the common overall pattern of thyroid function tests whilst receiving
therapy and TD outcomes, and the correlation with HCV status outcome.
Methods: A retrospective analysis of all medical records was performed to assess thyroid function
in Hepatitis C Virus (HCV) patients who were treated at the Hunter Area hepatitis C treatment
center between 1995 and March 2004. The centre is part of the John Hunter hospital, a major
tertiary referral centre in New South Wales, Australia.
Results: There were 272 cases available for review. The prevalence of TD is 6.7 percent and is
made up predominantly of females (80 percent). There were 3 (1.1 percent) cases of
hyperthyroidism with 2 (67 percent) females. Thirteen out of fifteen (80 percent) cases of
hypothyroidism were females with the overall prevalence of 5.5 percent. The majority of
hypothyroid patients still required Thyroxine supplement at the end of follow up.
Conclusion: Ninety three percent of HCV treated patients have intact thyroid function at the end
of treatment. The predominant TD is hypothyroidism. The predominant pattern of thyrotoxicosis
(TTX) is that of thyroiditis although the number is small. Graves' like disease was not observed.
People with pre-existing thyroid auto-antibodies should be closely monitored for thyroid
dysfunction, particularly hypothyroidism.
Background
Hepatitis C infection is one of the major epidemics afflict-
ing young adults with more than 150,000 known infected
cases in Australia and a notification rate of ~16,000 cases
per year in 2002 [1]. In the United States, HCV remains
the most common chronic blood-born infection [2,3].
The effective management of the new cases is critically
important because, without treatment, approximately
14,000 will develop chronic HCV infection, 6,500 will
develop HCV-related cirrhosis, 175 liver failure and 50
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with hepatocellular carcinoma. The treatment typically
involves the combination of IFN-α and RBV therapy. This
is an effective therapy with a 'cure' rate of up to 70%
depending on genotype as judged by the negative HCV
Ribonucleic Acid (RNA) polymerase chain reaction (PCR)
detection [4]. However, no treatment is free from compli-
cation and the use of IFN-α is well documented to be asso-
ciated with TD, the commonest autoimmune disorder
associated with IFN-α therapy. This study looks at the
combined effect of IFN-α and RBV in an exclusively Aus-
tralian group of patients with hepatitis C to determine the
pattern of thyroid behaviour with direct regards to eu-,
hyper- and hypo-thyroidism. The prevalence of hypothy-
roidism prevalence and outcome of treatment, in terms of
HCV RNA clearance, in direct relationship to thyroid con-
dition are both determined.
Methods
Patients
The cases of 272 patients who received combination ther-
apy between 1995 and end of March 2004 at the John
Hunter hospital Hepatitis C service were reviewed. All
other causes of chronic hepatitis were excluded. No
patient had dual Hepatitis B and C. Baseline characteris-
tics of all studied subjects are included in Table 1. Family
history of thyroid disease is not available other than in
patients who subsequently developed TD.
Laboratory assays
Serum autoantibodies to anti-thyroglobulin (anti-Tg) and
anti-thyroperoxidase (anti-TPO) were measured by agglu-
tination (Serodia-ATG and Serodia-AMC, Fujirebio, Inc.,
Tokyo, Japan). Titre of less than 1:400 was considered
normal for both. Thyroid Stimulating Immunoglobulin
(TSI) was measured using cell culture and radio-immu-
noassay. This is an in-house bioassay using Chinese Ham-
ster Ovary (CHO) cells in culture to detect the presence of
thyroid stimulating activity. The CHO cells are transfected
with the TSH receptor genes and thus are responsive to
TSI. Thyroid-stimulating activity is measured by evaluat-
ing the intracellular release of cyclic Adenosine Mono-
Phosphate induced by the patient's serum immunoglobu-
lin on the CHO cells. The results are reported as units/mL
(U/mL). TSI should be absent in the normal population.
A TSI level of <10 is considered negative, 10–50 as weakly,
50–100 as moderate and >100 U/mL as strongly positive.
Third generation serum thyrotropin (TSH), serum free
tetra- and free tri-iodothyronine (fT4 and fT3) were deter-
mined by two-site sandwich immunoassay using an
automated chemiluminescent system (Diagnostic Prod-
ucts Corporation, Immulite 2000). The reference range
(RR) for TSH was 0.4–4.0 mU/L, fT4 10.0–26.0 and fT3
3.5–5.5 pmol/L. The coefficients of variations (CV) were
5.0 % and 5.1 % at TSH concentrations of 4.0 mU/L and
10.0 mU/L respectively. For fT4, the CV was 6.5% at 10.0
pmol/L and fT3 8.9% at 3.5 pmol/L.
Therapy
All patients were treated with combination IFN-α and
RBV therapy. The duration of treatment depends on the
HCV genotypes; genotypes 2 and 3 were treated for 24
weeks and types 1 and 4 for 48 weeks respectively. Treat-
ment was continued to the end for the latter irrespective
of the HCV RNA status at 24 weeks. The dosage for IFN-α
was 3 MIU thrice a week with RBV dose ranging from
1000 to 1200 mg daily according to bodyweight.
Thyroid function assessments
All patients received routine thyroid function tests (TFT)
at the start of treatment and at monthly intervals. If there
was any concern, then the frequency was increased as clin-
ically indicated. Most, particularly the thyrotoxic group,
but not all patients were referred to the Endocrine service
for review. Thyroxine supplement was prescribed for
hypothyroidism when deemed clinically appropriate. All
patients were followed up for a period of 12 months after
the completion of anti-viral therapy. Some were followed
additionally for a longer period in the Endocrine outpa-
tient service. Thyroid autoantibodies were not routinely
Table 1: Baseline characteristics of 272 patients who received 
combination IFN-α and RBV therapy for HCV
Demographics
Mean age (years) 42 ± 8
Males 150 (55%)
Caucasians 204 (75%)
Asians 22 (8%)
Weight (kg) 79 ± 18
HCV Genotype
1 136 (50%)
22 2  ( 8 % )
3 103 (38%)
41 1  ( 4 % )
Liver Function Tests (RR)
Albumin (36–48 g/L) 41 ± 2
Serum Bilirubin (2–20 µmol/L) 15 ± 6
Alanine Aminotransferase (< 45 U/L) 133 ± 58
γ-Glutamyl Transpeptidase (1–30 U/L) 98 ± 46
Prothrombin time (11–18 seconds) 15 ± 3
Haematological Parameters (RR)
Haemoglobin (115–165 g/L) 142 ± 16
White cell counts (4.0–11.0 × 106/mL) 7.1 ± 2.0
Platelets (150–400 × 109/mL) 168 ± 49BMC Endocrine Disorders 2005, 5:8 http://www.biomedcentral.com/1472-6823/5/8
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performed until the patient developed hypo- or hyperthy-
roidism on clinical and/or biochemical grounds.
TTX was defined as having TSH of < 0.1 mU/L, fT4 levels
> 26.0 and/or fT3 levels > 5.5 pmol/L respectively.
Hypothyroidism, including subclinical hypothyroidism,
was defined as having TSH levels > 4.0 mIU/L. Thyroxine
supplement was, however, given when deemed clinically
appropriate regardless of the degree of TSH elevation.
Thyroid dysfunction
Thyroid dysfunction (TD) was defined as having hypo- or
hyper-thyroidism, (clinically and/or biochemically based)
Statistics
Data are presented as percentage and mean ± Standard
Error of Mean (SEM).
Results
Incidence of thyroid dysfunction in HCV treated group
The majority of patients (93%) had no TD at the end of
treatment. Amongst the 272 patients, there were a total of
18 (6.7%) cases of TD: 3 hyper-thyroidism and 15 hypo-
thyroidism.
There were 3 cases of pre-existing hypothyroidism
detected at baseline and thus were excluded from the
study. All cases were detected at the initial assessment for
the treatment of hepatitis C and were shown to have auto-
immune hypothyroidism requiring thyroxine supple-
ment. This gave a pre-treatment hypothyroidism preva-
lence of 1.1% (3/275). Hypothyroidism was seen in 15
(5.5%) with 12 (80%) females after treatment. Thirteen
(87%) patients required thyroxine therapy.
TTX was observed in 3 (1.1%) patients whose characteris-
tics are listed in Table 2. Two (67%) were females and all
required endocrinology attention. None had any thyroid
imaging studies and thus the diagnosis was made on clin-
ical grounds, auto-antibody detection and disease
behaviour.
Thyroid response to combination Interferon-α2B and RBV 
therapy
1.1 Euthyroid patients
Patients who were treated with IFN-α and had normal
TFTs were divided into 2 groups according to duration of
treatment: at 24 (n = 117) and 48 (n = 136) weeks respec-
tively. Both demonstrated a drop in TSH levels at about 4
months after entry into therapy. Interestingly, none of
these patients lowered their TSH level below 0.4 U/L. This
was followed by a return to pre-treatment levels and
remained so in the follow-up period. Results are illus-
trated in Table 3 and Figure 1.
1.2 Hypothyroid patients
All hypothyroid patients had non-specific symptoms and
relevant data are listed in table 4. Free T3 levels were not
routinely measured in the presence of hypothyroidism.
Table 2: The pattern of TTX in patients receiving combination IFN-α and RBVNo thyroid nuclear or ultrasonic imaging was available 
for all thyrotoxic cases
Subjects 1 2 3
Gender FFM
Age 26 35 36
HCV Genotype 1a 3a 1g
Regimen duration (weeks) 48 24 24
Adverse reactions Myalgia, lethargy, emotional lability None Insomnia, rash
Baseline ALT 184 142 104
ALT at time of thyroid disease 33 28 17
Duration of therapy prior to 
thyroid disease (weeks)
16 8 32
Symptoms of thyroid disease Anxiety and depression Non-specific Non-specific
Signs No goitre No goitre No goitre
Peak fT4 (pmol/L) 56.7 57.0 27.0
Peak fT3 (pmol/L) 15.1 15.3 12.8
Thyroid autoantibody status • Anti-Tg <1
• Anti-TPO 1:409,600
• TSI <1
• Anti-Tg <1
• Anti-TPO 1:409,600
• TSI <1
• Anti-Tg <1
• Anti-TPO <1:100
• TSI <1
Thyroid outcomes Hypothyroidism on replacement 
therapy
Hypothyroidism on replacement 
therapy
Thyroid condition resolved with 
IFN-α dose reduction
Hepatic outcomes PCR negative PCR negative PCR negativeBMC Endocrine Disorders 2005, 5:8 http://www.biomedcentral.com/1472-6823/5/8
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Anti-TPO antibodies were detected in 6 out of 15
hypothyroid patients (40%) with titres ranging from 1:
6,400 to 1: 409,600. The rest had titres <1:400. Baseline
autoantibodies were not routinely requested at the initial
assessment.
1.3 Hyperthyroid patients
All 3 thyrotoxic patients had suppressed TSH levels with
varying levels of fT4 and fT3. The time to development of
TTX was variable but most occurred whilst receiving treat-
ment. Anti-TPO antibodies were elevated in patients 1
and 2 (2 out of 3 cases) and both behaved in a thyroiditis
fashion. Hypothyroidism developed rapidly and Thyrox-
ine supplement was subsequently required within 1
month. In patient 3, despite the negative antibody results,
the TTX responded to a reduction in IFN-α dosage suggest-
ing an IFN-α/autoimmune mediated mechanism. TSI was
undetectable in all 3 patients.
All (100%) patients with thyroid dysfunction cleared their
hepatitis C infection based on the aforementioned criteria
The normal patterns of TSH response in hepatitis C patients during and after receiving combination IFN-α and RBV therapy in  the two treated groups at different durations Figure 1
The normal patterns of TSH response in hepatitis C patients during and after receiving combination IFN-α and RBV therapy in 
the two treated groups at different durations.
Table 3: TSH data for the 6 and 12 month treated cohorts who did not develop TD
T i m e  ( m o n t h s ) 0246 1 6
Mean TSH ± SEM (mU/L) for the 6 month treated cohort n = 117 1.62 ± 0.11 1.51 ± 0.12 1.29 ± 0.08 1.56 ± 0.13 1.76 ± 0.11
048 1 2 1 6
Mean TSH ± SEM (mU/L) for the 12 month treated cohort n = 
136
1.65 ± 0.15 1.31 ± 0.08 1.58 ± 0.17 1.57 ± 0.14 1.71 ± 0.16BMC Endocrine Disorders 2005, 5:8 http://www.biomedcentral.com/1472-6823/5/8
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against a background overall response rate of ~75% to the
combination anti-viral therapy in our cohort.
Discussion
This is the first report to characterise thyroid responses to
combination anti-viral treatment in an Australian cohort
with hepatitis C infection. The prevalence of TD is ~7% of
which 83% is hypothyroidism. The predominant gender
is female at 80%. This is consistent with previous reports
relevant to this condition [5-7]. The prevalence range is
broad reflecting the differences in the definition of TD,
some are biochemically based, others clinically based or
both.
Overall, 93% (254/272 cases) of patients have normal
thyroid outcome. In the majority of cases, the TSH levels
remain within reference range throughout. Levels
decrease slightly at 4 months but return to pre-existing
level with the continuation of treatment irrespective of the
duration of therapy. The range of TSH values is narrow
ranging between 1.15 at the 4-month nadir and 2.03 at 16
months in 95% of cases whilst undergoing therapy. FT4
levels were not routinely measured in the presence of
normal TSH levels which remain the single best assess-
ment of thyroid function in the presence of intact hypoth-
alamo-pituitary-thyroid axis [8], expected in this sub-
group. Whilst it is tempting to attribute the decrease in
TSH level during treatment to IFN-α and RBV, it is likely
that non-thyroidal illness is the main underlying patho-
genesis. Other co-morbidities associated with combina-
tion treatment (but particularly IFN-α) include fever,
headache, depression and neuropsychiatric disturbance
etc... all contribute to the changes in TFTs [9].
In TTX, the number is too small to arrive at any definitive
conclusions. Only the destructive thyroiditis form is
observed in this study. Goitre is absent in all cases. In
patients 1 and 2, this type of hyperthyroidism rapidly con-
verts to hypothyroidism in the presence of high auto-anti-
body titre and subsequently required permanent
Thyroxine supplement. In patient 3, the TTX was mild and
resolved with IFN dose reduction. This was presumed to
be IFN-α/autoimmune mediated despite the absence of
auto-antibodies. This pattern has been observed else-
where [10-12]. Unfortunately, radioactive iodine uptake
scans were not performed so that the diagnoses could be
unequivocally confirmed. TTX resembling Graves' disease
was not observed. In this scenario, TTX is uncommon and
thus each case should be dealt with on its own merits. The
index of clinical suspicion should remain high whilst on
therapy. Management is best done in a specialist Endo-
crine clinic, with destructive thyroiditis being more com-
mon, often resulting in permanent hypothyroidism.
Hypothyroidism is clearly the commoner cause of TD in
combination therapy. It has been suggested that the virus
itself may play a role in the development of hypothy-
roidism in IFN-naïve patients as the prevalence is higher
than the general population [13]. Also, if IFN-α alone is
thought to cause hypothyroidism, the prevalence of
hypothyroidism should be higher than in IFN-naïve
patients and this is the case of this report with a 5 folds
increase after treatment. However, this observation has
not been consistent in the general literature, see Table
5[14-19]. To further add to the complexity of the situa-
tion, hypothyroidism is also more frequent in patients
having combination therapy of IFN-α and RBV [20] (as
opposed to IFN-α treated alone). Whilst HCV is well
known to induce a higher prevalence of auto-antibody,
this does not necessarily translate into hypothyroidism
(either clinical or subclinical) [14]. It would have been
additionally interesting to characterize, in parallel, the
pattern of thyroid function in our HCV patients who did
not receive HCV treatment for direct comparison. Unfor-
tunately these data are not available.
The pathogenesis remains poorly understood but IFN-α is
thought to be related to have a direct inhibitory effect on
Table 4: Data for hypothyroid patients receiving combination therapy for Hepatitis C infection
Number of subjects 15 (9 treated for 48 weeks and 6 for 24 weeks)
Gender 3 M : 12 F
Mean age 44 ± 2
Positive family history of thyroid disease (in first degree 
relatives)
8/18 (44%)
Duration of IFN-α before thyroid disease developed (months) 4.8 ± 1.2
Mean TSH levels (mU/L) 29.7 ± 8.8
Mean fT4 levels (pmol/L) 3.5 ± 0.9
The presence of TPO-autoantibodies 6/15 (40%)
Thyroxine requirement at the 12-month follow-up 13/15 (87%)
PCR negativity at the end of treatment 15/15 (100%)BMC Endocrine Disorders 2005, 5:8 http://www.biomedcentral.com/1472-6823/5/8
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thyrocytes preventing hormonogenesis and secretion.
Another postulate is immunostimulation in the presence
of hepatitis C infection. This is thought to include activa-
tion of lymphocytes and natural killer cells, increased
production of Tumor Necrosis Factor, IFN-α, Interleukin
and other cytokines and increased production of immu-
noglobulins [21]. All lead to the development of thyroid
auto-antibodies with complete destruction and
consequently permanent hypothyroidism in genetically
susceptible individuals. Although this does occur in hep-
atitis B IFN-α treated patients, the prevalence of hypothy-
roidism is much lower. This suggests that the hepatitis C
virus or its genome plays an integral part the development
of thyroid dysfunction [10]. The virus itself has been pos-
tulated to induce thyroid auto-antibodies by ways of gen-
erating high endogenous  IFN levels triggering off
autoimmune thyroid disease in susceptible individuals,
similar to Coxsackievirus. This virus and others have been
shown to induce a higher level of endogenous IFN-α lev-
els which have been associated with other auto-immune
diseases such as type 1 diabetes [22]. When IFN-α is
administered exogenously, another layer of complexity is
added. It is possible but purely speculative that exogenous
IFN-α synergises with the endogenous source, thus exag-
gerating the effect on the thyroid thus causing additional
hypothyroidism.
Whatever the underlying pathophysiological process is,
the major factors contributing to hypothyroidism
includes the female gender with a relative risk ranging
between 3–7 times [23] and the presence of anti-TPO
antibodies (Ab). These factors feature prominently in our
report although the prevalence of anti-TPO Ab is lower.
The time to onset of biochemical hypothyroidism means
at about 5 months, similar to other cohorts [6].
When IFN-α triggers destructive thyroid disease in geneti-
cally susceptible individuals, some may recover but the
majority does not in our study. Thyroxine requirement
therefore is expected to be long term as illustrated in 87%
(13/15) of our cases. All 6 (100%) patients where anti-
TPO antibodies are detected, are on thyroxine at the com-
pletion of follow up. The symptomatology of hypothy-
roidism is non-specific and often overlaps with IFN-α
side-effects. The diagnosis often requires biochemical test-
ing with some patients receiving thyroxine supplement at
mildly elevated concentrations of TSH and/or low/nor-
mal fT4 levels. Where thyroxine was deemed necessary
and thus given, all were continued with thyroxine supple-
ment at 12-month follow-ups suggesting that thyroid
damage is permanent although longer follow-up is
preferred.
All patients with TD cleared their HCV infection up until
end of follow-up. The number is too small to make any
conclusion about the advantage of having thyroid dys-
function when it comes to eradicating the virus. Hypo-
thetically, these patients may have developed an
exaggerated response which helps to clear the virus and in
the process induces thyroid dysfunction, an unfortunate
but acceptable side-effect of the treatment modality.
Whilst this is highly plausible, it has not been supported
by other investigators [24].
Conclusion
IFN-α in combination with RBV therapy, by and large,
does not cause thyroid dysfunction in the majority of
HCV patients undergoing such treatment. Patients under-
going such therapy can expect a small decrease in TSH lev-
els, which remained in the RR however, without going
into frank hyper- or hypothyroidism. The incidence of TD
in HCV patients receiving combination anti-viral therapy
is generally small with hypothyroidism being the most
common. All patients should be assessed thoroughly for
relevant risk factors and monitoring for dysfunction at the
appropriate time frame. Hyperthyroidism is uncommon
Table 5: The prevalence of hypothyroidism in the IFN-naïve and IFN-treated HCV patients compared with the general populations. 
The prevalence of elevated TSH levels in the various population groups include: Australia ~2.0% [17], the United States of America 
~7.3% [18], Spain ~2.0% [18], Japan ~1.3% [18], Great Britain ~7.3% [18] and Italy ~1.7% [19]
Studies N = number of subjects Prevalence of hypothyroidism (before IFN) Prevalence of hypothyroidism (after IFN)
Marcellin et al. [5] N = 74 0 7.2
Preziati et al. [15] N = 78 0 22.8
Imigawa et al. [14] N = 58 0 3.4
Marazuela et al. [7] N = 207 4.7 2.8
This work N = 272 1.1% 7.5%
Baudin et al. [16] N = 68 0 7.3
Antonelli et al. [13] N = 630 13% N/ABMC Endocrine Disorders 2005, 5:8 http://www.biomedcentral.com/1472-6823/5/8
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and thus is best managed in a specialised Endocrine clinic.
The important points derived from this study are summa-
rized in Table 6.
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thyroid testing.
4. Predisposing risk factors include female gender, family history of thyroid disease and existing thyroid auto-antibodies, especially anti-TPO 
antibodies. In this situation, initial TSH should be performed to exclude pre-existing hypothyroidism.
5. Hyperthyroidism is less common and each should be managed on its own merits in a specialised Endocrine service.Publish with BioMed Central    and   every 
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